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ABSTRACT A gene-targeting construct was made con-
taining 7.8 kilobases of DNA spanning exon 10 of the mouse
cystic fibrosis transmembrane regulator (CFTR) gene in which
part of the exon has been replaced by two neomycin-resistance
(Neo) genes driven by different promoters. (This replacement
introduces a chain-termination codon at amino acid position
489 in the CFTR sequence.) A herpes simplex thymidine kinase
gene was on each end of the construct, which was electropo-
rated into embryonic stem (ES) cells. Colonies resistant to
G418, or to G418 plus ganciclovir, were selected and screened
by Southern blotting or by PCR amplification. Five pools of
G418-resistant cells gave PCR products diagnostic of targeting.
Four independent clones of ES cells with a disrupted CFTR
gene have been isolated from these pools. The frequency of
targeting was 1/2500 G418-resistant colonies. This low fre-
quency is not the consequence ofmarginal expression oftheNeo
genes in the targeted cells. The CFTR targeting events were
clustered among our experiments in a manner suggesting that
some unidentified factor(s), possibly passage number, influ-
ences the recovery of CFIR-targeted cells.
The most common mutation associated with cystic fibrosis is
the deletion of the three bases coding for phenylalanine-508
in exon 10 of the cystic fibrosis transmembrane regulator
(CFTR) gene (1). Homozygotes for this deletion have a severe
form of the disease, involving lung and pancreatic dysfunc-
tion. The effects of homozygosity for other types of mutant
CFTR alleles are now beginning to be described as a result of
the availability of PCR methods for their detection (2, 3). A
Soviet family with cystic fibrosis causing early death appears
to provide an example (4). Three infants died in this family
within months of birth (two with pneumonia and one with
presumed meconium ileus). The parents were shown to be
heterozygotes for a normal CFTR gene and a mutant allele
with a chain-termination codon at amino acid position 515, as
a result of deletion of two nucleotides in exon 10. While a
direct association between homozygosity for this mutant
CFTR gene and the occurrence of cystic fibrosis was not
established in this family (the genotypes of the deceased
infants were not determined), the data suggest that chain
termination of the CFTR protein within exon 10 is likely to
cause a severe form of cystic fibrosis. Similar conclusions
can also be reached by examining the phenotypes of individ-
uals having the phenylalanine-508 deletion mutation com-
bined with several different chain-termination mutants (Lap-
Chee Tsui, Toronto, personal communication).
No naturally occurring mutations are known that model
human cystic fibrosis. But mice have a single CFTR gene that
codes for a protein identical to the human protein in >78% of
its amino acids (5). We have therefore commenced studies
aimed at generating mice of two types: animals homozygous
for a CFTR gene disrupt-d by a chain-termination mutation
and animals homozygous for the phenylalanine-508 deletion.
Inactivation of a gene can be achieved by a single gene
targeting event involving homologous recombination be-
tween the target gene and exogenous DNA (6, 7). More subtle
changes, such as the deletion of nucleotides in a chosen
position within a coding sequence, currently require an initial
gene targeting step and then a second step in which sequences
introduced during the targeting step can undergo spontane-
ous excision to generate the desired change (8, 9).
We describe here experiments demonstrating that the
CFTR gene can be targeted in mouse embryonic stem cells in
a manner expected to lead to the introduction of a chain-
termination mutation at amino acid position 489 in exon 10.
Pluripotent embryonic stem (ES) cells modified in this way,
when injected into blastocysts, should allow the production
of animals with a genotype similar to that described in the
Soviet family.
MATERIALS AND METHODS
Targeting Plasmids. A bacteriophages containing DNA
from the CFTR gene of a strain 129 mouse were isolated,
using a mouse CFTR cDNA probe (5), from a library in
bacteriophage EMBL3 of genomic DNA partially digested
with Sau3AI. From one of these bacteriophages, a 14-
kilobase (kb) BamHI fragment containing exon 10 was iso-
lated by hybridization to a probe specific for human CFTR
exon 10 sequences. A plasmid KK50 was constructed that
contains the neomycin-resistance gene (Neo) from pMClNeo
(7), together with its promoter and enhancer, flanked at both
its 5' and 3' ends by a copy of the herpes simplex thymidine
kinase gene driven by the same promoter and enhancer (7).
The targeting plasmid pCF Neo was constructed from KK50
in two steps. First, a 700-base-pair (bp) fragment from the
14-kb BamHI fragment of the mouse CFTR gene, extending
from a Sty I site in intron 9 to the Xmn I site in exon 10, was
cloned into an Nhe I site located immediately 5' to the
pMClNeo sequences in KK50. Then a 7.1-kb fragment also
from the 14-kb BamHI fragment, extending from a Stu I site
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just 3' to exon 10 to an Nco I site in intron 10, was cloned into
a Sac II site located immediately 3' to the pMClNeo se-
quences in KK50. A second targeting plasmid, pCF Neo2 (see
Fig. 1), was constructed by codirectionally inserting an
additional Neo gene, driven by the phosphoglycerokinase
(PGK) promoter (10), into a Sal I site located 3' to the
pMC1Neo sequences in pCF Neo.
ES Cells. The ES cell line E14TG2a (11) was cultured in
some experiments on primary embryonic fibroblast feeder
layers that had been irradiated with 3000 rads (1 rad = 0.01
Gy); the fibroblast feeder cells were from (129/Ola x C57BL/
6J)F2 embryos carrying a copy of a neomycin-resistance
transgene in the i32-microglobulin locus (12) and can grow in
medium containing G418. In other experiments, no feeder
layers were used, but leukemia-inhibiting factor (LIF) (13)
was added that had been produced from COS-7 cells trans-
fected with the LIF-expressing plasmid pC106R (Genetics
Institute, Cambridge, MA); in these experiments, the culture
dishes were pretreated with 0.1% gelatin to facilitate cell
adhesion.
Electroporation. Electroporation in culture medium con-
taining 3-5 nM targeting plasmid was as described (14) except
with a 1-sec discharge from a 150- to 250-,uF capacitator
charged to 250-400 V. Prior to most of the electroporations,
the targeting sequences were excised from their plasmids by
digestion with Not I (see Fig. 1); excised sequences are
identified below by the same names as the plasmids but
without the letter p. In some experiments, the targeting
plasmids were linearized by cutting at a restriction site within
the vector plasmid sequences.
Selection. After electroporation, ES cells were plated onto
feeder layers (or cultured in the presence of LIF) in either
100-mm Petri dishes or in 24-well plates at dilutions that gave
between 10 and 60 drug-resistant colonies per 16-mm-
diameter culture well. For positive selection experiments,
G418 (Sigma) was present in the medium at a final concen-
tration of 200 ,ug/ml. For the positive-negative selection
experiments (15), ganciclovir (a gift from Syntex, Palo Alto,
CA) was present at a final concentration of 1 ,uM in addition
to the G418. After 10-14 days, colonies were tested for
targeting by Southern blotting or by PCR amplification.
Southern Blot Analysis. Colonies were expanded to a level
sufficient for Southern blot analysis, which was carried out
conventionally using either a BamHI/Sty I probe specific for
CFTR sequences (see Fig. 1) or one specific for the Neo gene.
PCR Primers. Primers 1 and 3 (see Fig. 1) are specific to the
incoming DNA; their sequences are as follows: primer 1,
5'-ACACTGCTCGAGGGCTAGCCTCTTC-3'; primer 3, 5'-
ACACTGCTCGACATTGGGTGG-3'. Primers 2 and 4 (see
Fig. 1) are specific to the target locus; their sequences are as
follows: primer 2, 5'-CAGTGAAGCTGAGACTGTGAGC-
TT-3'; primer 4, 5'-CCACAATGAGAGGCTGAGACA-3'.
PCR-Positive Control Cell Line. A PCR-positive control
cell line having primers juxtaposed in the way they occur in
correctly targeted cells (see Fig. 1C) was made by transform-
ing E14TG2a ES cells with plasmid F141.1. This plasmid was
constructed by cloning into the Nhe I site located 5' to the
Neo sequences in KK50 a 1.2-kb fragment from the 14-kb
BamHI fragment of the mouse CFTR gene DNA, extending
from the 5' BamHI site (in intron 9) to the Xmn I site in exon
10 (see Fig. 1A). Lysates from ES cells targeted at the CFTR
locus in the desired manner should give the same PCR signals
after amplification with primers 1-4 as do lysates from this
control cell.
PCR Amplification. Cell lysates were prepared as de-
scribed (16). PCR amplification was typically in 50 Al of
buffer containing each dNTP at 50 ,uM, 0.4 ,g ofeach primer,
50 mM Tris HCl (pH 8.5), 1.5 mM MgCl2, 20mM (NH4)2SO4,
10% dimethyl sulfoxide, and 0.2 unit of Taq polymerase.
Denaturation was for a minimum of 30 sec at a maximum
temperature of 920C. Extension was for 10 min at 650C. Cycle
number was 35. Pools of cells or pools of colonies were
considered PCR positive when an amplified lysate equivalent
to 50,000 cells gave, after electrophoresis, visible stained
bands of the sizes diagnostic of targeting (see Figs. 1 and 2):
1050 bp for primers 1 and 2, and 1100 bp for primers 3 and 4.
Lysates from 1:10 and 1:100 mixtures of the PCR-positive
control cells with the starting ES cells were used to check
amplifications. When lysates from single targeted colonies
were being amplified, stained bands were readily seen with
-500 cells.
RESULTS AND DISCUSSION
Targeting Strategy. Fig. 1 shows the targeting strategy. The
targeting constructs contain =7.8 kb of mouse genomic DNA
that spans exon 10 of the CFTR gene but with one (CF Neo)
or two (CF Neo2) copies ofthe positively selectable Neo gene
in place of the 3' two-thirds of exon 10 and 200 bp of the 5'
end of intron 10. Homologous recombination between the
target CFTR locus (Fig. 1A) and the targeting construct CF
Neo or CF Neo2 (Fig. 1B) leads to a modified gene (Fig. 1C)
that now contains the positively selectable gene(s) and should
code for a truncated CFTR protein with amino acid 488
changed to alanine (from isoleucine) and with a stop codon
(UAG) at position 489 (Fig. 1D). Cells containing the modi-
fied gene are expected to be resistant to the antibiotic G418.
The targeting constructs also have a copy of the negatively
selectable herpes simplex thymidine kinase gene (TK in Fig.
1) on their 5' and 3' ends to allow use ofthe positive-negative
selection protocol of Mansour et al. (15). Screening for
targeting can be carried out directly by Southern blotting the
DNA from candidate colonies. As shown in Fig. 1, several
fragments increase in length by =3 kb after targeting. Alter-
natively, screening can be by PCR amplification using pairs
of primers that yield fragments of a predicted size only with
DNA from targeted colonies (16). Primers 1 and 3 are specific
for the incomingDNA and primers 2 and 4 are specific for the
target locus; only when the odd-numbered primers are jux-
taposed to the even-numbered primers by targeting will
amplification give the correctly sized fragments (1050 with
primers 1 and 2; 1100 with primers 3 and 4).
Detection of Targeted Colonies in Pools ofES Cells. ES cells
were electroporated in the presence of the targeting con-
structs CF Neo or CF Neo2 and plated under the appropriate
selective conditions on embryonic fibroblast feeder layers or
in the presence of LIF.
Table 1 summarizes all our experiments and their results.
Experiment 1 was with the targeting construct CF Neo,
which is the same as CF Neo2 shown in Fig. 1 but without the
PGK Neo insert. The treated cells were exposed to G418 and
ganciclovir in the positive-negative selection protocol of
Mansour et al. (15). Over 300 doubly resistant colonies were
picked individually and tested directly for targeting by South-
ern blotting. None was targeted.
To allow comparison of experiments using positive-
negative selection with those using only positive selection,
we determined an "enrichment factor" (Table 1) for each
doubly selected experiment by measuring, on convenient
aliquots of the electroporated ES cells, the ratio of colonies
resistant to G418 alone to colonies resistant to both G418 and
ganciclovir. The number of colonies that would have been
found had we used only G418 selection can then be calculated
by multiplying the number of (G418 + ganciclovir)-resistant
colonies by the enrichment factor. This value is also pre-
sented in Table 1 in the column G418 equivalents.
As a precaution against the possibility that the single copy
of the Neo gene in CF Neo might not be expressed at a
sufficiently high level to confer G418 resistance when em-
bedded in the CFTR locus, we next introduced into the
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FIG. 1. (A) Exon 10 and its surroundings in the mouse CFTR gene. (B) The targeting construct CF Neo2 (see text for details). (C) The CFTR
gene expected after targeting. (D) Details of the nucleotide and deduced amino acid sequences (numbered) predicted for the junction between
the 5' part of exon 10 and MClNeo after targeting; italicized amino acids are not coded by the normal CFTR gene. Restriction sites important
in construction of the targeting DNA or used for analysis of targeted colonies are shown. B, BamHI; K, Kpn I; N, Nco I; 0, Not I; S, Sst I;
U, Stu I; X, Xmn I; Y, Sty I; sites in parentheses were destroyed during ligation. Sites and directions of primers 1-4 used for PCR analysis are
indicated. Wavy lines show the amplified fragments that are characteristic of targeting. The sizes of some restriction enzyme fragments used
for Southern analysis are indicated; vertically hatched box shows the BamHI/Sty I CFTR-related probe used for hybridization.
targeting construct a second Neo gene, driven by the strong
and ubiquitously expressed PGK promoter (10). The result-
ing construct, CF Neo2 (shown in Fig. 1), was used in all
subsequent experiments.
In experiments 2, 3A, 4A, 5, 6A, and 7, a total of 1501
doubly resistant colonies were individually picked and PCR
tested (corresponding to 5995 G418 equivalents) together
with 212 individually picked colonies resistant to G418 alone
Table 1. Screening of drug-resistant colonies and isolation of targeted colonies
G418R PCR- Targeted
colonies (G418 + ganciclovir)R Enrichment G418 positive colonies
Experiment Protocol screened colonies screened factor equivalents pools isolated
1 F, I 303 8.1 2454 * 0
2 F, I 606 3.8 2303 0 0
3A F, I 55 3.8 209 0 0
4A F, I 54 5.0 270 0 0
5 F, I 48 6.8 326 0 0
6A F, I 344 5.3 1823 0 0
7 L, I 394 2.7 1064 0 0
3B F, I 87 0 0
4B F, I 125 0 0
6B F, P 578 1 1
8 L, P 580 2 1
9 F, P 475 1 1
10A F, I 294 0 0
10B F, P 2,098 0 0
11 F, P 1,146 0 0
12 F, P 452 0 0
13 L, P 875 0 0
14 L, P 1,890 0 0
15 L, P 3,738 1 1
Total 12,338 1804 8449 5 4
G418R, resistant to G418 alone; (G418 + ganciclovir)R, resistant to both G418 and ganciclovir. Experiments are numbered
according to their time sequence but have been grouped by screening protocol; experiment 1 was with CF Neo, all others
were with CF Neo2; colonies in experiments 3, 4, 6, and 10 were screened in one of two ways as indicated by A and B.
Protocol is designated as follows: using cells on feeder layers (F) or LIF-adapted (L), with screening individually picking
colonies (I) or by testing while still in pools (P). Enrichment factor, separately measured on suitable aliquots, is number
of G418R colonies divided by number of (G418 + ganciclovir)R colonies. G418 equivalents are number of (G418 +
ganciclovir)R colonies screened x enrichment factor.
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(in experiments 3B and 4B). Again, none was targeted, even
though we found, as expected, that CF Neo2 gave more (by
a factor of -3) G418-resistant colonies than were obtained
with CF Neo.
We next considered the possibility (disproved below) that
even the two Neo genes in construct CF Neo2 might not be
expressed when integrated into the target CFTR locus. If this
were so, it might still be possible to isolate targeted cells
without depending on expression of the Neo gene in the
CFTR gene. Thus, Reid et al. (17) have recently demon-
strated that selecting for the expression of a Neo gene
integrated into the genome nonhomologously gives survivors
that are enriched for targeting, although the enrichment is
much less than with conventional G418 selection. We there-
fore removed ganciclovir from the selection medium, so that
nonhomologous integrants with CF Neo2 could be tested for
CFTR targeting. To enable the screening oflarger numbers of
colonies, PCR testing was carried out directly on small pools
of colonies without picking them individually.
In experiments 6B, 8, and 9, respectively, 578, 580, and 475
G418-resistant colonies in pools of -8 visible colonies were
tested by PCR. The ES cells for experiments 6 and 9 were
cultured on feeder layers; the cells for experiment 8 were
cultured in LIF-containing medium without feeder layers. A
pool giving a positive PCR signal was identified in the
G418-resistant pools from experiments 6B and 9, and two
positive pools were identified from experiment 8. Fig. 2
illustrates the detection of these PCR-positive pools.
At this point, E14TG2a ES cells with a lower passage
number (around 20) were used, and six more experiments,
10-15, were carried out with the construct CF Neo2. A total
of 10,493 G418-resistant colonies were screened in these six
experiments, mostly in pools of 15-60 visible colonies. Not
until experiment 15 was another PCR-positive pool identi-
fied.
Thus, we identified a total of five pools giving PCR signals
indicating successful targeting (of which four are certainly
independent since they were from different electroporations)
from a total of >12,000 G418-resistant colonies, screened in
pools, and >1800 individually picked colonies resistant to
both G418 and ganciclovir (corresponding to >8400 G418
equivalents). Some clustering of positive pools is apparent in
the data summarized in Table 1.
Isolation of PCR-Positive Clones. ES cells from the five
PCR-positive pools were treated with trypsin and replated
onto fibroblast feeder layers in the presence of G418. Indi-
vidual colonies were picked and divided into two portions-
one as a replica and one for furtherPCR tests. In this manner,
we were able to isolate PCR-positive colonies from four ofthe
five PCR-positive pools identified in the course of our ex-
periments.
Analysis of the Isolated Clones. PCR-positive clones iso-
lated in the previous step were expanded to a level sufficient
for testing their genomic DNA by Southern blot analysis. The
simplest characteristic of correctly targeted cells (Fig. 1C) is
that the size of restriction fragments spanning exon 10 should
increase by 2.7 kb. Fig. 3 shows the results of digesting DNA
from four colonies isolated in experiments 6B and 8 in Table
1 with Sst I or Kpn I and comparing Southern blots of these
digests to those from the starting ES cells (E14TG2a). Hy-
bridization was to a probe specific for sequences in intron 9
of the CFTR gene (see Fig. 1). The correctness of targeting
in both colonies was established by the blots, which showed
that one of the two CFTR alleles has now increased in size by
2.7 kb. Identical results were obtained with other isolates of
PCR-positive cloned cells. Tests with other restriction en-
zymes, including BamHI, EcoRV, and EcoRI, gave patterns
(data not shown) that completely agreed with the correctness
of the targeting. The exogenous DNA had only inserted into
the target locus, as judged by the absence of any hybridizing
bands (other than the targeted fragment), when the Southern
blots were probed with a Neo gene probe specific for the
incoming DNA (data not shown). The absence of any non-
homologously integrated copies of the Neo gene excludes the
possibility that cotransformation played any role in isolating
the targeted colonies.
Factors Affecting Targeting. Although our experiments
demonstrate that the CFTR gene in mouse E14TG2a ES cells
can be modified by gene targeting, the frequency of targeting
is low- 1/2500 cells transformed to G418 resistance. We
have attempted to identify a feature(s) responsible for this
low frequency. One possibility is that expression of the Neo
gene(s) when incorporated into the CFTR gene is too low to
ensure survival of all targeted cells in medium containing
G418. Against this possibility is our observation (data not
shown) that cells targeted at the CFTR locus with CF Neo2
survive perfectly well in medium containing 400 ,ug of G418
per ml, which is twice that used during selection.
1 23 4 5 6 7 8910
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FIG. 2. Agarose gel electrophoresis of PCR-amplified lysates
from pools of colonies of G418-resistant ES cells. Lanes 1-16,
samples from pools 8.34-8.49 from experiment 8 in Table 1 (con-
taining -10 colonies per pool) after PCR amplification with primers
1 and 2 (see Fig. 1). Pools 8.34 (lane 1) and 8.37 (lane 4) show the
amplified fragment (right pointing arrowhead) characteristic of tar-
geting. Lanes 18 and 19, samples from pools previously giving
negative results. Lanes 20, 21, and 24, samples from a pool (6.35) that
had given positive results in experiment 6B in Table 1. Lanes 22 and
23, samples of the positive control cells (see text) mixed with
untargeted ES cells at ratios of 1:100 and 1:10. Lanes 25 and 26 and
lanes 27 and 28, samples of pool 6.35, and of the 1:100 and 1:10 mixes
ofthe positive control cell, respectively, after PCR amplification with
primers 3 and 4; the size of the amplified fragment (left pointing
arrowhead) is that expected for a targeted cell with these two
primers. Lane 17, size marker.
5.7-
3.0-
FIG. 3. Southern blots of targeted ES cells with a probe that
hybridizes to CFTR sequences from intron 9 (see Fig. 1). Genomic
DNA from two colonies from experiment 6B (lanes 1, 2, 6, and 7),
two from experiment 8 (lanes 3, 4, 8, and 9) and from the starting ES
cells (lanes 5 and 10) digested with Sst I (left blot), and Kpn I (right
blot). The sizes of the fragments are indicated in kb.
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The CFTR-targeting events detected were clustered in a
manner suggesting that the ES cells were easier to target at
some times than at others. Thus, a cluster of targeting events
was observed in experiments 6, 8, and 9, and none was
detected again until experiment 15. A variable that appears to
parallel this distribution is the passage number of the ES cells
being treated. The ES cells at the beginning of our work were
early passage cells (passage number, -20); by experiments
6-9 the passage number had exceeded 50. Experiment 10 was
with freshly thawed low-passage ES cells (passage number,
=16); it was negative after screening more G418-resistant
colonies than gave four PCR-positive pools in experiments
6-9. Not until experiment 15 with LIF-adapted cells (passage
number, >50) was targeting again observed. These data
suggest but do not prove that obtaining CFTR targeted cells
is easier with later passage ES cells. Unfortunately, the
frequency at which ES cells can contribute to the germline
when injected into blastocysts decreases with increase in
passage number. Comparison oftargeting at a different locus,
the hypoxanthine phosphoribosyltransferase (HPRT) locus,
reveals a similar trend (data not shown). Thus, the ratio of
targeting the HPRT locus with pMP8 (17) to transformation
with pMC1 Neo (7), when both plasmids were introduced
simultaneously, changed from -0.1 with LIF-adapted ES
cells at passage number 25 to -0.9 at passage number >50.
Determining the reproducibility and significance of these
trends requires additional studies.
Our failure to detect any CFTR-targeting events in >1800
(G418 + ganciclovir)-resistant colonies (equivalent, when
corrected for enrichment, to >8000 G418-resistant colonies)
requires comment in light of our detection of -1 event for
every 2500 colonies selected only in G418. It could be a
reflection of the effect of passage number, since the double-
selection experiments were with lower passage cells than the
G418 experiments. It could be because small colonies may be
missed when they are individually picked and pooled before
PCR testing (all doubly selected colonies were individually
picked), while comparable colonies give a detectable PCR
signal when screened in a preexisting pool (essentially all
singly selected colonies were in pools). It is not due to some
unexpected sensitivity of the CFTR-targeted cells to ganci-
clovir, since we found them fully resistant to ganciclovir at
twice the concentration used in selection.
Conclusion. Although there are some complicating features
in targeting the CFTR gene in ES cells by homologous
recombination, our data show unequivocally that targeting
exon 10 of the gene is possible and is reproducible.
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